Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN

Inclusion Criteria: * European Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * no severe cognitive compromise * Moderate risk chemotherapy induced chemotherapy induced nausea and vomiting in 1st cycle * Confirmed histology Exclusion Criteria: * European Cooperative Oncology Group (ECOG) performance status of 3 and 4 * Nausea or vomiting in the 24 hours before enrollment * History of Nausea or vomiting Grade 3 before previous chemotherapy * Known history of central nervous system disease (e.g., brain metastases or a seizure disorder) * Bowel obstruction * Serum creatinine level of 2.0 mg per deciliter (177 μmol per liter) or more * Aspartate or alanine aminotransferase level that was more than 3 times the upper limit of the normal range * Treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, a phenothiazine, or a butyrophenone within 30 days before enrollment * Treatment with another antiemetic agent before 48 hours before enrollment * Uncontrolled severe infection or uncontrolled severe comorbidity * Concurrent abdominal radiotherapy * Known hypersensitivity to olanzapine, palonosetron * Known cardiac arrhythmia, uncontrolled congestive heart failure, or acute myocardial infarction within the previous 6 month